Researcher Ups Count of UC NIH Basic Cancer Research Study Section Members

Maria Czyzyk-Krzeska, MD, PhD, professor in UC’s Department of Cancer Biology and a member of both the Cincinnati Cancer Center and the University of Cincinnati Cancer Institute, will serve as a member of the Molecular Oncogenesis Study Section, Center for Scientific Review, for the National Institutes of Health from July 2015 through June 2021. Members are selected on the basis of their competence and achievement in their scientific discipline and by the quality of their research accomplishments, publications in scientific journals and other significant scientific activities, achievements and honors. 

In addition to Czyzyk-Krzeska, fellow cancer biology faculty and CCC and institute members David Plas, PhD, and Susan Waltz, PhD, serve as NIH study section members. Plas serves in the Tumor Cell Biology Study Section; Waltz serves in the Cancer Molecular Pathobiology Study Section. Together, faculty members in cancer biology now serve as regular members in three of the seven NIH study sections that focus on basic mechanistic cancer research.

"(Our department is) well represented within the NIH basic cancer research study sections, which from the perspective of a relatively small basic science department, is really a strong reflection of faculty strength and achievement,” says Cancer Biology Director Jun-Lin Guan, PhD, adding that Carolyn Price, PhD, a professor in the department, also serves in the Molecular Genetics A Study Section. "This is a fantastic display of the talents and efforts of our faculty, and I hope that this will help in the upward trajectory of NIH funding for these faculty members as well as others within the department and across the UC College of Medicine.”

>>Read about other UC representation in NIH study sections.

Related Stories

2

At least two weather patterns increase headaches, UC study suggests

June 4, 2026

University of Cincinnati physicians and collaborators identified two specific weather patterns that increase headache and migraine risk and found the preventive medication fremanezumab (Ajovy) can reduce weather‑associated headaches. The findings will be presented at the American Headache Society Annual Scientific Meeting in Orlando.